MCL1 and cancer: Kotschy et al. (2016 ▸) highlighted the importance of the pro-survival protein myeloid cell leukaemia 1 (MCL1) as a target for small molecules amenable for clinical testing to potentially kill MCL1-dependent cancer cells by activating the BAX/BAK-dependent mitochondrial apoptotic pathway.